Our study thus far reveals that both pharmacological and genetic perturbation of MYC activity leads to upregulation of the metabolic enzyme GFAT1 and enhanced glycosylation in prostate cancer models (Figure 1-2). The gene discussed is GFPT1; the disease is prostate carcinoma.